Marshall Wace
ARQT icon

Marshall Wace’s Arcutis Biotherapeutics ARQT Stock Holding History

Marshall Wace’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.3M Buy
2,431,778
+1,977,545
+435% +$50.5M 0.06% 317
2025
Q4 		$13.2M Buy
454,233
+435,933
+2,382% +$11.2M 0.01% 771
2025
Q3 		$345K Buy
+18,300
New +$289K ﹤0.01% 2374
2025
Q2 		– Sell
-57,908
Closed -$906K – 2686
2025
Q1 		$906K Buy
+57,908
New +$816K ﹤0.01% 1828
2024
Q1 		– Sell
-95,011
Closed -$307K – 2423
2023
Q4 		$307K Sell
95,011
-2,216,066
-96% -$6.02M ﹤0.01% 1882
2023
Q3 		$12.3M Sell
2,311,077
-6,464
-0.3% -$55K 0.03% 581
2023
Q2 		$22.1M Buy
2,317,541
+12,205
+0.5% +$135K 0.05% 442
2023
Q1 		$25.4M Buy
+2,305,336
New +$33.4M 0.06% 378
2022
Q4 		– Sell
-167,816
Closed -$3.21M – 2925
2022
Q3 		$3.21M Buy
+167,816
New +$3.8M 0.01% 1700
2021
Q3 		– Sell
-15,138
Closed -$413K – 3007
2021
Q2 		$413K Sell
15,138
-154,349
-91% -$4.35M ﹤0.01% 2216
2021
Q1 		$4.9M Buy
169,487
+90,514
+115% +$2.83M 0.03% 855
2020
Q4 		$2.22M Buy
+78,973
New +$1.93M 0.01% 909

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return